175 related articles for article (PubMed ID: 22727345)
21. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
Gallos ID; Devey J; Ganesan R; Gupta JK
Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
[TBL] [Abstract][Full Text] [Related]
22. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
23. Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium.
Arnett-Mansfield RL; DeFazio A; Mote PA; Clarke CL
J Clin Endocrinol Metab; 2004 Mar; 89(3):1429-42. PubMed ID: 15001645
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
25. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
26. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
[TBL] [Abstract][Full Text] [Related]
27. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium.
Bozdoğan O; Atasoy P; Erekul S; Bozdoğan N; Bayram M
Int J Gynecol Pathol; 2002 Oct; 21(4):375-82. PubMed ID: 12352186
[TBL] [Abstract][Full Text] [Related]
28. Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses.
Marra C; Penati C; Ferrari L; Cantù MG; Bargossi L; Fruscio R
Gynecol Endocrinol; 2014; 30(12):899-901. PubMed ID: 25111756
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
[TBL] [Abstract][Full Text] [Related]
31. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.
Rattanachaiyanont M; Angsuwathana S; Techatrisak K; Tanmahasamut P; Indhavivadhana S; Leerasiri P
J Obstet Gynaecol Res; 2005 Apr; 31(2):98-106. PubMed ID: 15771634
[TBL] [Abstract][Full Text] [Related]
33. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
34. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Vereide AB; Kaino T; Sager G; Arnes M; Ørbo A
Gynecol Oncol; 2006 May; 101(2):214-23. PubMed ID: 16325240
[TBL] [Abstract][Full Text] [Related]
35. Endometrial hyperplasia with secretory changes.
Tresserra F; Lopez-Yarto M; Grases PJ; Ubeda A; Pascual MA; Labastida R
Gynecol Oncol; 2003 Mar; 88(3):386-93. PubMed ID: 12648591
[TBL] [Abstract][Full Text] [Related]
36. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
[TBL] [Abstract][Full Text] [Related]
37. Expression of Stromal Progesterone Receptor and Differential Methylation Patterns in the Endometrium May Correlate with Response to Progesterone Therapy in Endometrial Complex Atypical Hyperplasia.
Neal AS; Nunez M; Lai T; Tosevska A; Morselli M; Amneus M; Zakhour M; Moatamed NA; Pellegrini M; Memarzadeh S
Reprod Sci; 2020 Sep; 27(9):1778-1790. PubMed ID: 32124398
[TBL] [Abstract][Full Text] [Related]
38. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
Gunderson CC; Fader AN; Carson KA; Bristow RE
Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711
[TBL] [Abstract][Full Text] [Related]
39. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.
Reed SD; Newton KM; Garcia RL; Allison KH; Voigt LF; Jordan CD; Epplein M; Swisher E; Upson K; Ehrlich KJ; Weiss NS
Obstet Gynecol; 2010 Aug; 116(2 Pt 1):365-373. PubMed ID: 20664397
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
